Peptide administration for lung fibrosis treatment using formulation based on medusa technology. develop a sustained release formulation os p144 or p17, loquid or freeze-dried form, for subcutaneous administration route and carry on preclinical and clinical trials.
Invitrotek ltd. Sti. (Istanbul, turkey) and pronto diagnostics ltd. (Tel aviv, israel) will collaborate in developing an assay, based on the targeted next generation sequencing to detect mutations in all thalassemia cases.
To investigate the possibility of developing biomarkers for hcc prognosis and companion diagnostics by using advanced sequencing technologies (ngs) and the data analysis algorithms for a set of target biomarkers.
Development of a comprehensive in silico platform for the prediction and analysis of protein - noble gas interactions and potential therapeutic applications across the entire human proteome.